A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.

The aim of this trial is to investigate whether pre-operative treatment with chemotherapy plus radiation therapy has a better outcome than chemotherapy alone in patients undergoing surgery for resectable gastric cancer.

Primary Sponsor

Australasian Gastro-Intestinal Trials Group (AGITG)

Collaborating Groups

TROG Cancer Research; Canadian Cancer Trial Group (CCTG); European Organisation for Research & Treatment of Cancer (EORTC); National Health and Medical Research Council Clinical Trials Centre (NHMRC CTC)

Accrual Target

570

Final Accrual

574

Expected Date of Accrual

31 December 2020

Closing Date of Accrual

May 2021

Trial Chairperson

Professor Trevor Leong, Peter MacCallum Cancer Centre, VIC

Trial Contact

topgear.study@sydney.edu.au

Related Post

Prof Paul Keall, Image X Director and VITaL trial chief investigator
15 May, 2025

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

LATEST NEWS: 15 May 2025 A novel imaging modality

HeSANDA database for clinical trial data
21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is